DMAC
NASDAQDiaMedica Therapeutics Inc.
Price$6.73-0.02 (-0.30%)
01:30 PM07:45 PM
News · 26 weeks31+500%
2026-03-012026-08-23
Mix1990d
- Insider10(53%)
- Other4(21%)
- SEC Filings3(16%)
- Earnings2(11%)
Latest news
25 items- INSIDERPresident & CEO Pauls Dietrich John was granted 60,200 units of Voting Common Shares, increasing direct ownership by 88% to 128,791 units (SEC Form 4)4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- SECSEC Form S-8 filed by DiaMedica Therapeutics Inc.S-8 - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- SECSEC Form 10-Q filed by DiaMedica Therapeutics Inc.10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- SECDiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- PRDiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsEnrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027 $43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027 Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time DiaMedica Therapeutics Inc. (NASDAQ:DM
- PRDiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its second quarter 2026 financial results will be released after the markets close on Monday, August 10th. DiaMedica will host a live conference call on Tuesday, August 11th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, August 11, 2026 Time: 8:00 AM EDT / 7:00 AM CDT Web access: https://app.webinar.net/d01wEPk9peA Dial In:
- PRDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in July 2026. The stock options were a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation. The stock options were approved by the Compensation Committee of the Board of Directors and issued
- PRDiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth RestrictionFirst clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alf
- PRDiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical ProgramDiaMedica planning to conduct a rat pharmacokinetic and activity study, which it believes will address FDA-requested data for a preeclampsia IND DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. investigational new drug (IND) appl
- INSIDERSEC Form 4 filed by Director Giuffre Randall Michael4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Kuntz Richard4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director O'Connor Daniel J.4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Lewis Tanya4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Semba Charles Pauling4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Parsons James T.4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Pauls Dietrich John4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by CFO & Secretary Kellen Scott4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Krop Julie4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- PRDiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 3:45 PM ET Format: Corporate Presentation If you are interested in arranging a 1×1 meeting with management, please contact your conference representative. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving t
- SECDiaMedica Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- PRDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim Analysis Interim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging Between 300 and 728 Patients) is Recommended Interim Analysis Anticipated to be Completed Before Year-End 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the
- PRDiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its President and CEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th in New York City. Fireside Chat Details Date & Time: Tuesday, May 19, 2026 | 4:05-4:30 PM ET Location: InterContinental New York Barclay NY | 111 E 48th Street, New York, NY 10017 Mr. Pauls will also be available for one-on-one meetings with investors during the conference. About DiaMedica Therapeutics Inc. DiaM
- SECSEC Form 10-Q filed by DiaMedica Therapeutics Inc.10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- SECDiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- PRDiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsDM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment; Interim Analysis planned in 4Q 2026 $51.3 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027 Conference Call and Webcast on May 7 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the
DMAC FAQ
7 questionsWhat does DiaMedica Therapeutics Inc. do?
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica...Where does DMAC stock trade?
DiaMedica Therapeutics Inc. (DMAC) is listed on NASDAQ.What sector and industry is DMAC in?
DiaMedica Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did DiaMedica Therapeutics Inc. go public?
DiaMedica Therapeutics Inc. (DMAC) completed its IPO in 2018.What are analysts saying about DMAC?
DiaMedica Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2025-11-14. Recent price targets range from $700.00 to $3200.00.What companies are similar to DMAC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DMAC side-by-side with any of them on Quantisnow.How can I track DMAC on Quantisnow?
Quantisnow aggregates DiaMedica Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DMAC to receive live email and push alerts on every new disclosure.